Nana Rokutanda

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +14

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 254 citations · Full text

Medicine, Oncology, Pharmacology +11

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Clinical Oncology · 2022 · 235 citations

Medicine, Oncology, Pharmacology +17

Expression and Mutations of KCNJ5 mRNA in Japanese Patients with Aldosterone-Producing Adenomas

Ryo Taguchi, Masanobu Yamada, Yasuyo Nakajima et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 176 citations

Medicine, Endocrinology, Genetics +11

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial

Howard A. Burris, Takuji Okusaka, Arndt Vogel et al. · The Lancet Oncology · 2024 · 132 citations

Medicine, Oncology, Pharmacology +11